Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Medical House and Dr Reddy's enter licensing deal

This article was originally published in Scrip

Executive Summary

The Medical House (TMH), a specialist in drug delivery, has signed a non-exclusive development, licensing and supply agreement withDr Reddy's Laboratories. Under the terms of deal, TMH will customise its proprietary, patented ASI disposable auto-injector device technology as per an agreed specification. This technology allows injections to be easily and safely undertaken by patients or other non-clinicians and is suitable for both elective therapies and emergency situations. Dr Reddy's will combine the customised auto-injector device with an undisclosed drug, to create a new self-injectable product. The agreement covers an initial five-year supply term within the US, EU and Canada, with an option for Dr Reddy's to extend the deal to the rest of the world on mutually agreed terms. The development costs associated with customisation will be paid to TMH in addition to reimbursement of all agreed external costs. First commercial supply of the customised ASI device is expected to be in 2009-10 and TMH will receive a technology access fee during the term of the agreement. TMH's projected revenue over the first five years is estimated at £5 million.

You may also be interested in...

Roche’s Tecentriq Gets Another Indication In India But Pricing Hurts

Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.

Chiesi Files India Legal Action Against Cipla Over Respiratory Therapy Patent

The Italian firm has initiated legal proceedings in India against Cipla, alleging infringement of a patent for an inhalation therapy.

Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry

Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts